Comment from Anonymous

I am submitting this comment as a concerned citizen who believes the FDA's core mission — ensuring biological products are safe, effective, and properly studied — was not fully upheld in the transition of the Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines from Emergency Use Authorization to full Biologics License Application approval. I am not anti-vaccine. I am pro-science and pro-accountability, and it is precisely because I believe in rigorous drug regulation that I raise these concerns. The EUA-to-BLA transition bypassed standard evidentiary requirements. The FDA's own guidance has historically required sponsors to complete well-controlled clinical investigations before full licensure. The BLA approvals for Comirnaty and Spikevax departed from this standard. Trials were still ongoing at approval. Long-term safety data was unavailable. Follow-up periods were substantially shorter than those required for other novel biologics. Multiple regulatory scholars with no ideological opposition to vaccines have noted that the FDA's own guidelines were applied selectively. The public health emergency does not suspend the agency's obligation to ensure the evidentiary record is sufficient. I urge the FDA to publicly account for each standard requirement it modified and explain how those departures were legally and scientifically justified. The risk-benefit calculus has also shifted significantly. At the pandemic's height, the argument that benefits outweighed risks was strongest for elderly and vulnerable populations facing life-threatening illness. That context has changed. Population immunity is now widespread, and COVID-19 no longer represents the same severity of threat it did in 2020–2021. Risk-benefit analysis is not static — it must be reassessed as conditions change, a principle the FDA acknowledges in its own framework. A rigorous, updated, population-stratified risk-benefit analysis is urgently needed, and continued licensure should require sponsors to demonstrate that original benefit conclusions still hold under current epidemiological conditions. Post-market surveillance has also revealed harms demanding a regulatory response. Peer-reviewed literature has documented myocarditis and pericarditis — particularly in males aged 12–39 — at rates exceeding background levels following second and booster doses. Menstrual irregularities were not investigated in pre-licensure trials but have since been documented in multiple studies. Neurological adverse events remain incompletely characterized. The existence of adverse events does not automatically mean a product should be removed from the market, but these harms must be fully characterized and honestly weighed against benefits for each population group. Critically, the FDA's post-market study commitments attached to these BLAs have not been completed on schedule, and sponsors have faced minimal consequences for delays. This is unacceptable for any licensed biological product. I am asking the FDA to: conduct a transparent review of whether the BLA evidentiary record met the agency's own published standards; require updated population-stratified risk-benefit analyses reflecting current conditions; enforce post-market study commitments on a mandatory timeline with full public disclosure; and mandate additional clinical investigation for populations — particularly children and young adults — where trial data was most limited and the risk-benefit profile is least clear. These are not radical requests. They are the ordinary expectations of rigorous drug regulation. The urgency of the pandemic was understandable, but it cannot permanently lower the evidentiary bar for products administered to hundreds of millions of Americans. The FDA exists to protect the public — not to protect prior regulatory decisions. If the licensure process did not fully meet the agency's own standards, the appropriate response is to correct it. Do the science that should have been completed before full licensure was granted. The American public deserves nothing less.